Editorial: Stem cell follies: Crank up the spin machine
By Sacramento Bee,
Sacramento Bee
| 07. 17. 2005
Just a half year into its troubled existence, California's stem cell research institute has already spent more than $2 million, none of it on research. Alert members of the institute's 29-member oversight board are starting to ask an important question: Where the heck is this money going?
Despite a cash-flow shortage caused by a pair of costly lawsuits, institute chairman Robert Klein II has been spending freely. Four months ago, under Klein's direction, the institute quietly hired Edelman, which bills itself as the "world's largest independent public relations group," at a rate of $27,550 a month. Edelman replaced Redgate Communications, which had already racked up $108,000 in PR work in three months.
Klein didn't use a competitive bidding process in retaining either of these companies. Neither did he seek competitive bids before he hired the law firm of Remcho, Johansen & Purcell for $320,000. At the moment, he and institute President Zach Hall are negotiating a long-term contract with Edelman that could top $500,000.
Oversight board members learned of these expenditures at a meeting in Irvine last Tuesday, and some...
Related Articles
By Editors, Nature | 08.18.2026
Shinya Yamanaka doesn’t see himself as a celebrity. But people do recognize the stem-cell researcher when he’s out for a run, often while training for a marathon, on the streets of Kyoto, Japan.
Many of them call out words of...
By Jessica Hamzelou, MIT Technology Review | 07.30.2026
As of this week in Montana, any biotech company with an experimental drug has a clear path to selling it to consumers. Companies whose drugs have been through preliminary testing—sometimes in as few as 10 healthy people—can pay $12,500 to...
By Carl Zimmer and Marco Hernandez , The New York Times | 07.01.2026
Scientists have long dreamed of discovering the alchemy by which chemicals can be turned into life. On Wednesday, a team at the University of Minnesota announced that it had taken a major step toward that vision.
Blending together dozens of...
By Marisa Flook , BioNews | 06.29.2026
An anti-ageing gene therapy not approved by the US Food and Drug Administration (FDA) is set to be offered by an American company at overseas clinics outside of US jurisdiction.
The treatment, developed by Minicircle from Austin, Texas, uses a...